Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Slides:

Advertisements

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Advertisements

Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force by.

Figure Flow of funds for a 340B agreement for fingolimod

Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure EDSS, FS scores, and Modified MSFC scores

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 3 Archetypal MS clinical course depicted over 20 years

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure 1 Patient flow diagram

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 2 Forest plots for subgroup analyses

Figure 2. ROC curves for different group comparisons

Figure 3 Temporal trends in FALS incidence

Figure 1 Characteristics of the German National MS Cohort

SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.

Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.

Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.

Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.

Nat. Rev. Neurol. doi: /nrneurol

Decline in the risk of carotid occlusion with more intensive medical therapy. Decline in the risk of carotid occlusion with more intensive medical therapy.

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 3 Longitudinal performance of 2 MS–cohabitant participant pairs on Ishihara color testing Both response speed and response accuracy are provided.

Figure 4 Confirmatory cohorts to assess MOG-IgG1 assay(A) All 81 aquaporin-4 (AQP4)- seropositive patients (blue) from the Oxford National neuromyelitis.

Figure 1 Proportions of the major B-cell subsets in DMF-treated patients Proportions of the major B-cell subsets in DMF-treated patients B cells were collected.

Figure 1. Antibodies to MOG in a proportion of adult patients with MS

Figure 3 Correlation of lipid indexes to MRI measures of disease severity in multiple sclerosis Correlation of lipid indexes to MRI measures of disease.

Figure 2 Reduced frequency of central memory CD4 T cells in patients with PML Reduced frequency of central memory CD4 T cells (CD4Tcm) (p < ), naive.

Figure 1 Examples illustrating gating strategy for fluorescence-activated cell sorting (FACS)‏ Examples illustrating gating strategy for fluorescence-activated.

Figure 1 Anti-Epstein-Barr virus nuclear antigen-1 IgG quartile antibody status differences in MRI measures Anti-Epstein-Barr virus nuclear antigen-1 IgG.

Figure 1 Patterns of study retention The proportion of individuals actively participating in the study is displayed over the course of the study. Patterns.

Figure 3 Pedigrees of 3 multiplex families with NLRP3 mutations and MS The patient numbers refer to the patients listed in table 1. Pedigrees of 3 multiplex.

Figure Overview of patients with demyelinating diseases, presence of clinical symptoms frequently associated with NMDAR encephalitis, and antibody status.

Figure 2 Summary of the utility of MOG-Abs and OCB testing in predicting pediatric disease course at onset compared to clinical follow-up at 1 yearFollowing.

Figure 1 Percentage distribution according to severity of baseline behavioral changes in behavioral variant frontotemporal dementia (bvFTD) and semantic.

Figure Molecular structure Molecular structure of delta-9-tetrahydrocannabiol (THC) (left), which has psychoactive properties, compared to molecular structure.

Figure 1 Considerations for concussed athletes leading to medical care or return to sport (RTS)‏ Considerations for concussed athletes leading to medical.

Figure 2 Correlation between wGRS and age at onset The figure shows the correlation between weighted genetic risk score (wGRS) and age at onset in all.

Figure 2. Patient stratification by the reported duration of symptoms and disease severity at the time of assessment Patient stratification by the reported.

Figure 2 Quality stages by disorder The x-axis lists each of the quality improvement and practice-based research projects in order of implementation at.

Figure 1 Full-length MOG cell-based assay using a serum dilution of 1:160 as a cutoff for positivity (red line in both plots)(A) Myelin olidgodendrocyte.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure 4 Four representative disease-course archetypes

Figure 2 Frequency of the proportion of total WMLs with central veins in PPMS, RRMS, and SVD Frequency of the proportion of total WMLs with central veins.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise.

Figure 2 Assessment of fluctuation in fatigue scores using environmental data The relationship between fatigue (as measured by the Modified Fatigue Impact.

Figure Meta-analysis of 9 studies of patients with attention-deficit/hyperactivity disorder (ADHD) vs controls Meta-analysis of 9 studies of patients with.

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

Figure 2 Seizure outcomes

Figure 2 Overview of apheresis therapies

Figure Interactive world map

Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521

Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504

Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453

Figure 3 Freedom from clinical disease activity during 36 months of fingolimod treatment Freedom from clinical disease activity during 36 months of fingolimod.

Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and.

Suggested algorithm of addressing non-motor symptoms in clinic (modified from Chaudhuri et al).48 HCP, healthcare professional; QoL, quality of life; PDSS,

Figure 2 Time from incident ADS event to MS diagnosis

Location of common clinically relevant mutations in EGFR

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Figure Prevalence for MS cumulated over 10 years in the United States per 100,000 population by age and sex 2010 Prevalence for MS cumulated over.

Figure 4 Illustration of a practice effect by examining longitudinal performance measures in patients with MS and cohabitants (A) Response time for each.

Standard Protocol Items: Recommendations for Interventional Trials diagram. Standard Protocol Items: Recommendations for Interventional Trials diagram.

Figure 2 Segmented time series of median annual cost in the United States for first-generation multiple sclerosis disease-modifying therapies relative.

Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.

Presentation transcript:

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials The frequency of reporting of primary and secondary outcome measures in 58 MS DMT clinical trials used to inform MS DMT guideline development are depicted (ordered as in Figure 1). QoL = quality of life. Published with permission Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;90;777–788. doi: 10.1212/WNL.0000000000005347. Gregory S. Day et al. Neurol Clin Pract 2018;8:179-185 © 2018 American Academy of Neurology